[Case of Borrmann III stomach cancer effectively treated by UFT therapy (co-administration of uracil and futraful)].
Through X-ray and endoscopic examination of stomach, a 77 year-old man, who complained of epigastralgia, he was diagnosed to have Borrmann III type gastric carcinoma on the antrum. The gastric biopsy specimen obtained from the tumor revealed to be well differentiated adenocarcinoma. Since the patient refused receiving surgical treatment, a combined administration of futraful and uracil (UFT therapy) was performed. 4 weeks after receiving UFT therapy, the patient became less aware of subjective symptom and the gastrofiberscopic picture showed smaller mass lesion compared to that of prior to the treatment. 8 weeks later, the tumor was remarkable reducing its size. When compared 14 cases of gastric carcinoma receiving UFT therapy with 26 cases receiving Futraful therapy (FT therapy), the UFT group responded more effectively than the FT group. In the UFT therapy, complete (CR) and partial response (PR) were obtained in 4 of 13 cases of gastric carcinoma with an effective rate of 30.8% according to the response criteria proposed by the Koyama-Saitoh group and with a Karnofsky scale of IA or better in 6 (42.8%) of 14 cases. On the other hand, in the FT therapy CR and PR were obtained in 5 of 26 cases with that of 19.2%, while a Karnofsky scale of IA or better was achieved in 6 (23.1%). As for 3 cases of PR in the UFT therapy the microscopic view of the biopsy specimen from gastric carcinoma showed well differentiated adenocarcinoma, which responded to the UFT therapy remarkably 4-5 weeks after receiving UFT therapy.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000284:Administration, Oral; D000368:Aged; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage*
D005641:Tegafur; D005472:Fluorouracil